Other Significant Agreements - Additional Information (Details)		6 Months Ended	12 Months Ended	63 Months Ended
	Nov. 06, 2018 USD ($) shares	Jun. 30, 2022 USD ($) Milestone	Dec. 31, 2020 USD ($)	Feb. 01, 2021 USD ($)	Jun. 30, 2021 USD ($)	Nov. 30, 2015 USD ($)
MD Anderson Cancer Center | Patent and Technology License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining funding amount for patent-related costs under license agreement		$ 0
Number of days of prior written notice to terminate agreement		180 days
Number of milestones achieved | Milestone		0
Payments with respect to license agreement		$ 0			$ 0
MD Anderson Cancer Center | Patent and Technology License Agreement | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Patent costs				$ 1,500,000
MD Anderson Cancer Center | Patent and Technology License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent future payments upon achievement of certain development and regulatory approval milestones						$ 11,900,000
Contingent payments in cash or through issuance of equity						4,400,000
MD Anderson Cancer Center | Patent and Technology License Agreement | Maximum | Diagnostic Products
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent future payments upon achievement of certain development and regulatory approval milestones						2,400,000
MD Anderson Cancer Center | Patent and Technology License Agreement | Maximum | Therapeutic Products
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent future payments upon achievement of certain development and regulatory approval milestones						$ 9,500,000
Kayla Therapeutics S.A.S | Kayla License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of days of prior written notice to terminate agreement		30 days
Payments with respect to license agreement		$ 0
Royalty term determination period after first commercial sale of such product in such country		10 years
Number of days of notice to terminate agreement upon material breach		60 days
Kayla Therapeutics S.A.S | Kayla License Agreement | Phase 1/2 Clinical Trial
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of milestones achieved | Milestone		0
Non-refundable milestone payment in cash	$ 15,000,000.0
Non-refundable milestone payment in common stock | shares	177,318
Milestone payment			$ 15,000,000.0
Kayla Therapeutics S.A.S | Kayla License Agreement | Maximum | Phase 1/2 Clinical Trial
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Obligated to make cash payments upon achievement of clinical and regulatory milestones	$ 100,000,000.0
Value of common stock shares payable upon achievement of clinical and regulatory milestones	$ 13,000,000.0